NASDAQ:URGN - Nasdaq - IL0011407140 - Common Stock - Currency: USD
9.955 +0.27 (+2.73%)
UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer.
Mentions: RAPP PLUG WOLF CX ...